# SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

> **NCT04803877** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 48 (estimated)

## Conditions studied

- Osteosarcoma
- Osteosarcoma in Children
- Osteosarcoma Recurrent
- Osteosarcoma Metastatic

## Interventions

- **DRUG:** Regorafenib 40 MG
- **DRUG:** Regorafenib 20MG
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04803877
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-04
- **Primary completion:** 2025-11
- **Final completion:** 2026-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803877, "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04803877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*